July 22, 2023

Mage Bi­o­log­ics de­buted Thurs­day with a $28 mil­lion com­mit­ment from TVM Cap­i­tal Life Sci­ence and spe­cial­ty phar­ma com­pa­ny Tillotts Phar­ma. The new biotech is cen­tered

Idor­sia could cut “up to 500 po­si­tions” in R&D and as­so­ci­at­ed sup­port func­tions as the Swiss drug­mak­er finds ways to save cash un­til it can

The en­zyme en­gi­neer­ing spe­cial­ists at Codex­is are giv­ing up on mak­ing their own ther­a­pies, in­stead fo­cus­ing on sell­ing its tech­nolo­gies and ser­vices to cus­tomers —

Pa­tients with a rar­er form of acute myeloid leukemia now have a front­line treat­ment op­tion for the first time, thanks to the FDA’s ap­proval of

A chunky chain neck­lace, match­ing ear­rings, and a flo­ral shirt with a dozen col­ors — that’s Ig­or Splaws­ki. The for­mer chief sci­en­tist at Cure­Vac has

ADC Ther­a­peu­tics says it plans to stop a mid-stage study of Zyn­lon­ta in un­fit or frail pa­tients with large B cell lym­phoma. The Thurs­day af­ter­noon

Turn­stone Bi­o­log­ics raised $80 mil­lion in a Fri­day morn­ing IPO un­der the tick­er $TS­BX, book­end­ing a rare two-week stretch for biotech list­ings. The start­up fol­lows

Map­Light Ther­a­peu­tics, a biotech fo­cused on cen­tral ner­vous sys­tem dis­or­ders, is eye­ing a large $175 mil­lion fi­nanc­ing as it beefs up the C-suite and ad­vances

Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) was linked to higher risks of progression and death among patients with breast cancer, according

The Senate Health, Education, Labor & Pensions (HELP) Committee voted 17-3 with relatively little fanfare Thursday to send pandemic preparedness legislation to the full Senate